1. High-throughput human primary cell-based airway model for evaluating influenza, coronavirus, or other respiratory viruses in vitro
- Author
-
Jeffrey T. Borenstein, E E Marr, Robert W. Finberg, Jenna L. Balestrini, Jehan Alladina, Gaibler R, Hesham Azizgolshani, C A Wong, Brett C. Isenberg, R Fennell Fezzie, T J Mulhern, Benjamin D. Medoff, D M Burns, R J Luu, R. Maloney, Jonathan R. Coppeta, Ashley L. Gard, Pengpeng Liu, B P Cain, Jennifer P. Wang, and C. R. Miller
- Subjects
0301 basic medicine ,Science ,medicine.medical_treatment ,Cell Culture Techniques ,Bronchi ,Microbial Sensitivity Tests ,Respiratory Mucosa ,Biology ,medicine.disease_cause ,Antiviral Agents ,Article ,Cell Line ,03 medical and health sciences ,0302 clinical medicine ,Pandemic ,Influenza, Human ,medicine ,Influenza A virus ,Humans ,Respiratory Tract Infections ,Coronavirus ,Multidisciplinary ,Protease ,Respiratory tract infections ,SARS-CoV-2 ,virus diseases ,COVID-19 ,Equipment Design ,Microfluidic Analytical Techniques ,Virology ,In vitro ,High-Throughput Screening Assays ,COVID-19 Drug Treatment ,030104 developmental biology ,Cell culture ,Viral infection ,Medicine ,Coronavirus Infections ,Immortalised cell line ,Biomedical engineering ,030217 neurology & neurosurgery - Abstract
Influenza and other respiratory viruses present a significant threat to public health, national security, and the world economy, and can lead to the emergence of global pandemics such as from COVID-19. A barrier to the development of effective therapeutics is the absence of a robust and predictive preclinical model, with most studies relying on a combination of in vitro screening with immortalized cell lines and low-throughput animal models. Here, we integrate human primary airway epithelial cells into a custom-engineered 96-device platform (PREDICT96-ALI) in which tissues are cultured in an array of microchannel-based culture chambers at an air–liquid interface, in a configuration compatible with high resolution in-situ imaging and real-time sensing. We apply this platform to influenza A virus and coronavirus infections, evaluating viral infection kinetics and antiviral agent dosing across multiple strains and donor populations of human primary cells. Human coronaviruses HCoV-NL63 and SARS-CoV-2 enter host cells via ACE2 and utilize the protease TMPRSS2 for spike protein priming, and we confirm their expression, demonstrate infection across a range of multiplicities of infection, and evaluate the efficacy of camostat mesylate, a known inhibitor of HCoV-NL63 infection. This new capability can be used to address a major gap in the rapid assessment of therapeutic efficacy of small molecules and antiviral agents against influenza and other respiratory viruses including coronaviruses.
- Published
- 2021